Liver Cancer News and Research

RSS

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.

CTRC-AACR San Antonio Breast Cancer Symposium presents new data on emerging breast cancer therapies

Breast cancer continues to be a dynamic field of research, and the CTRC-AACR San Antonio Breast Cancer Symposium, now in its 32nd year, is the premier destination to present new data on emerging therapies.

14 Dec 2009

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced results from two collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trials were presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS).

14 Dec 2009

Research article addresses the relationship between PEG and GER

Gastroesophageal reflux (GER) is a common problem in mechanically ventilated patients and contributes to the development of esophageal mucosal injury and even erosive esophagitis. The relationship between percutaneous endoscopic gastrostomy (PEG) and subsequent development of GER is complex and not well understood.

9 Dec 2009

Research article on Peliosis hepatis

Peliosis hepatis (PH) is a rare pathological entity. PH varies from minimal asymptomatic lesions to larger massive lesions that may present with cholestasis, liver failure, portal hypertension, avascular mass lesion, or even spontaneous rupture.

9 Dec 2009

Comparative study on erosive and nonerosive diseases

Gastroesophageal reflux disease (GERD) is defined as the pathological retrograde movement of gastric contents into the esophagus. Various esophageal motility disturbances which may be important in reflux are observed in patients with GERD.

9 Dec 2009

Utility of CEH-EUS uses sonographic contrast agent to diagnose pancreatic tumors

Endoscopic ultrasonography (EUS) is a highly sensitive diagnostic method for the detection of small pancreatic carcinomas. Recently, there have been some reports describing the utility of contrast-enhanced harmonic EUS (CEH-EUS) which uses sonographic contrast agent for differentiation of a pancreatic mass.

9 Dec 2009

Phase II clinical trial results of Doxorubicin Transdrug announced

BioAlliance Pharma SA, a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announces positive survival data in its phase II clinical trial with doxorubicin Transdrug® in patients with advanced hepatocellular carcinoma (primary liver cancer).

9 Dec 2009

Rise in cancer rates linked to excessive alcohol consumption

There has been a significant increase in cancers which are linked to alcohol over the past ten years, according to figures requested by the Liberal Democrats.

9 Dec 2009

$Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma$

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Onyx Pharmaceuticals, Inc. today announced results from an ongoing Phase 2 study, known as the 004 study, of the company's lead proteasome inhibitor, carfilzomib.

8 Dec 2009

Updated safety data from Phase 2b 003-A1 study of carfilzomib announced

Onyx Pharmaceuticals, Inc. today announced updated safety data from the pivotal Phase 2b 003-A1 study, known as the 003 trial, demonstrating that carfilzomib is well-tolerated in heavily pre-treated relapsed and refractory multiple myeloma patients.

7 Dec 2009

New SPC3649 drug found effective in treating HCV infections

In a dramatic finding, a new drug for hepatitis C virus (HCV) infections that targets liver cells produced a substantial drop in blood levels of the virus in animals and continued to work up to several months after treatment, say scientists at the Southwest Foundation for Biomedical Research (SFBR) in San Antonio.

4 Dec 2009

Santaris Pharma's LNA technology based microRNA-targeted therapy holds promise for HCV

A study published online in this week's Science shows that SPC3649, a breakthrough microRNA-targeted therapy developed by Santaris Pharma A/S using its proprietary Locked Nucleic Acid (LNA) technology, holds promise as a novel treatment for patients infected with the Hepatitis C virus (HCV).

4 Dec 2009

Update on Celsion's ThermoDox Phase III “HEAT” trial for HCC

Celsion Corporation, a leading oncology drug development company, today provided an update on the progress of its pivotal ThermoDox® Phase III “HEAT” trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer. Following recent regulatory approvals in China, Malaysia, Thailand and the Philippines, the study is now enrolling patients in eleven countries, with the majority of clinical sites located in the Asia Pacific region where HCC is most prevalent.

3 Dec 2009

University of Pittsburgh's McGowan Institute for Regenerative Medicine awarded IBM SUR grant

The University of Pittsburgh's McGowan Institute for Regenerative Medicine, which connects scientists who work on tissue engineering, cell therapies, artificial organs and biodevices, has been awarded a Shared University Research (SUR) Award from IBM ( IBM). The IBM SUR Award will provide IBM computer hardware, software and services to Pitt for its cutting-edge "in silico" biological research, which uses computer simulations to explore biological pathways and test therapeutic interventions.

2 Dec 2009

Positive data from Provectus Pharmaceuticals' psoriasis and atopic dermatitis trials

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced preliminary data for the company’s PH-10 Phase 2 clinical trial for Psoriasis as well as for its Phase 2 clinical trial for Atopic Dermatitis.

1 Dec 2009

DFG approves establishment of new CRCs; research topics range from modern prostheses to political reforms to marine bacteria

The DFG has approved the establishment of 17 new Collaborative Research Centres as of 1 January 2010. This decision was made recently by the relevant Grants Committee in Bonn.

1 Dec 2009

Researchers devise a way to deliver right therapy directly to tumors using aptamers

Finding and treating a tumor without disturbing normal tissue presents challenges - sometimes the most effective therapies can be invasive and harsh.

1 Dec 2009

Healthy dietary habits are important for GCA prevention

The gastric cardiac adenocarcinoma (GCA) is a very rare disease. In recent decades, however, the incidence of the GCA has increased dramatically in many Western countries. An increasing trend in GCA is also observed in municipal regions but not in rural regions of China. Another striking feature is the strong male predominance among patients with GCA. Some of the reasons above are still unclear and require further epidemiological investigations.

26 Nov 2009

HPA-specific shRNA holds potential as a novel therapeutic strategy for gastric cancer

Previous studies have indicated that the heparanase (HPA) is correlated with histopathological parameters and poor prognosis of gastric cancers. Although their efficiencies in inhibiting the expression of HPA, the traditional HPA inhibitors may produce nonspecific and undesirable effects. In recent years, genetic approaches targeting HPA have been regarded as a promising alternative.

25 Nov 2009

Human Genome Sciences submits BLA for ZALBIN

Human Genome Sciences, Inc. today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C. The BLA submission includes the results of two pivotal Phase 3 clinical trials showing that 900-mcg albinterferon alfa-2b dosed every two weeks met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) dosed once each week.

25 Nov 2009

Liver Cancer News and Research

Further Reading

CTRC-AACR San Antonio Breast Cancer Symposium presents new data on emerging breast cancer therapies

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Research article addresses the relationship between PEG and GER

Research article on Peliosis hepatis

Comparative study on erosive and nonerosive diseases

Utility of CEH-EUS uses sonographic contrast agent to diagnose pancreatic tumors

Phase II clinical trial results of Doxorubicin Transdrug announced

Rise in cancer rates linked to excessive alcohol consumption

Phase 2 study of carfilzomib shows promising results in patients with refractory multiple myeloma

Updated safety data from Phase 2b 003-A1 study of carfilzomib announced

New SPC3649 drug found effective in treating HCV infections

Santaris Pharma's LNA technology based microRNA-targeted therapy holds promise for HCV

Update on Celsion's ThermoDox Phase III “HEAT” trial for HCC

University of Pittsburgh's McGowan Institute for Regenerative Medicine awarded IBM SUR grant

Positive data from Provectus Pharmaceuticals' psoriasis and atopic dermatitis trials

DFG approves establishment of new CRCs; research topics range from modern prostheses to political reforms to marine bacteria

Researchers devise a way to deliver right therapy directly to tumors using aptamers

Healthy dietary habits are important for GCA prevention

HPA-specific shRNA holds potential as a novel therapeutic strategy for gastric cancer

Human Genome Sciences submits BLA for ZALBIN

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News